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Abstract  
BACKGROUND: IDH1 (isocitrate dehydrogenase 1) mutation might be encounter in the low grade 
glioma and directs the progression of the tumor to a higher grade.  
OBJECTIVE: To assess the frequency of IDH1 mutations in gliomas and to correlate the IDH1 
positivity with the type and grade of tumors, the age and sex of the patients. 
MATERIAL AND METHODS: A retro– and prospective case series study. One hundred and nine 
cases of intracranial gliomas were collected between 2008 and 2014 from Mosul Private 
Laboratories and Al-Jamboree Teaching Hospitals in Mosul. IDH1 mutations were assessed 
immunohistochemically using anti-IDH1 R132H mouse monoclonal antibody. 
RESULTS: IDH1 mutation was perceived in 34.86% of gliomas. In adult gliomas, the secondary 
glioblastoma and the low-grade astrocytoma had the greatest values of IDH1 positivity (88.88% and 
62.5% respectively), followed by oligoastrocytoma/oligodendroglioma (50.0%), and anaplastic 
astrocytoma (47.36%). The primary glioblastomsa showed 17.64% IDH1 positivity. Males and 
females expressed the IDH1 equally. While, there was no role of IDH1 in pediatric gliomas. 
CONCLUSION: IDH1 mutation is commonly present in adult gliomas particularly in low-grade 
gliomas, and secondary glioblastoma, with equal sex distribution, but it has no role in pediatric 
gliomas.  
 
 
 
 
 
Introduction 
 
Glial tumors (or gliomas) account for 40%–
45% of all primary intracranial tumors.  Therefore, 
they are considered the most common type of primary 
brain tumors. Gliomas are classified as grade I to 
grade IV according to histopathological and clinical 
criteria established by the WHO [1]. This group of 
tumors includes specific histologic subtypes, the most 
common of which are astrocytomas, 
oligodendrogliomas, and ependymomas [1]. WHO 
grade I gliomas, has an indolent growth, often 
considered to be benign, and rarely, if ever, evolve 
into higher-grade lesions. By contrast, gliomas of 
WHO grade II or III are aggressive tumors, usually 
invasive, progress to higher-grade lesions, and have a 
poor outcome [1]. 
Progression of glioma to a higher grade tumor 
is multistep process involving many genes and 
characterized by genetic alterations and mutation 
accumulation, these include TP53, PTEN, CDKN2A, 
and EGFR [2]. Recent studies suggested that 
mutations in the gene encoding for cytosolic NADP+ 
dependant IDH1 (isocitrate dehydrogenase 1) might 
occur after the formation of a low-grade glioma and 
direct the progression of the tumor to a glioblastoma 
[3, 4]. 
IDH1 is a member of IDH gene family, located 
on chromosome 2q33.3 and encodes for the cytosolic 
NADP+ dependant isocitrate dehydrogenase enzyme. 
The product protein catalyze the cytosolic oxidative 
decarboxylation of isocitrate to alpha-ketoglutarate, 
and resulting in the production of reduced form of 
NADP+ (NADPH) which is play an important role in 
the cellular control of oxidative damage [5-7]. Gene 
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mutation alters the enzymatic property of IDH1 and 
leads to increase conversion of alpha-ketogluterate to 
2-hydroxyglutarate (2HG) metabolite and decreased 
production of NADPH, and accordingly reduced 
glutathione. These alterations may raise the oxidative 
stress level in mutant IDH1 cells and acting as an 
oncogen [8-10].  
IDH1 mutation has been observed as an early 
evidence and in high frequency (50%-93%) among 
astrocytomas, oligodendrogliomas, oligodendro-
gliomas and secondary glioblastomas, while rarely 
occurs in primary glioblastoma [2-6,11,12].  
Mutant IDH1 anaplastic astrocytomas, 
glioblastomas and oligodendroglial tumors have 
independent favorable prognostic factor particularly 
for grade III gliomas, and usually associated with 
increased progression-free survival and overall 
survival and may exceed other genetic markers. 
Interestingly, the few primary glioblastomas with IDH1 
mutations also have a significantly better prognosis [5, 
13-16]. 
The aim of this study was to validate the 
frequency of IDH1 mutation in gliomas in the Mosul 
city and to correlate the IHD1 positivity with the type 
and grades of gliomas, and with age and sex of the 
patients.  
 
 
Material and Methods 
 
This is a retro- and prospective case series 
study. In a period extended between 2008 and 2014, 
all types of intracranial gliomas of both sex and all age 
groups in the Mosul city were included in this study. 
Study carried out in Mosul Private Laboratory and in 
Al-Jamboree Teaching Hospital. The biopsies were 
processed histopathologically and paraffin-embedded 
blocks were sectioned on 4 micron thickness. Tumors 
proved to be gliomas were taken and were classified 
and graded according to last WHO Classification of 
the Central Nervous System Tumors [1]. Hereupon, 
109 biopsies of adult, male and female, and pediatrics 
intracranial gliomas were collected with their clinical 
data including age and sex, MRI findings of site and 
side of affection and the provisional clinical diagnosis.  
Ethical Approval was obtained from both 
Health Office and Medical College Ethical Review 
Committees. 
  
Immunohistochemical technique 
Four micron thickness slides were 
deparaffinized and rehydrated. Antigen retrieval was 
carried out by autoclaving at 95-99
0
C, for 20 minutes 
using retrieval solution (citrate puffer 10 mmol/L, pH 
6.0). Sections then allowed cooling to a room 
temperature, followed by washing 3 times, each for 3 
minutes, in phosphate buffered saline (PBS). 
Endogenous peroxidase activity was blocked by 
dipping sections in 3% hydrogen peroxidase blocker 
(Dako) for 10 minutes and washed in 3 changes of 
PBS. Sections were incubated with 1:20 diluted 
primary antibodies anti-human IDH1 R132H (Dianova, 
GmbH, Hamburg, Germany, Mouse Monoclonal 
Antibody Clone H09) for 60 minutes, followed by 
washing twice for 3 minutes changes of PBS. 
Detection system using 2-steps polymer of HRP MR-
2C, Polymer Detection Kit (Dianova Anti-Mouse, 
Rabbit, Universal Ms/Rb, PHA-70844) applied for 35 
minutes for each step. Sections were washed twice by 
PBS and visualized using 3,3-diaminobenzidine (DAB) 
for 5-10 minutes. Finally, the sections were lightly 
counterstained with hematoxylin, dehydrated and 
mounted. Negative control sections were treated in 
the same way, but by the substitution of primary 
antibody with PBS. Positive control sections were 
taken from positive cases and were performed in each 
batch of staining.  
Positive result show strong cytoplasmic 
staining which appears only in the tumor cells. 
Expression of IDH1 was determined by visual 
semiquantitative assessment of the proportion of the 
positively stained tumor cells. Cases with ≥10% cells 
as positive, and cases with <10% cells were rated as 
negative [2, 13].  
 
Statistic analysis 
Data were interpreted in form of frequencies 
and percentage. A chi square (
2
) test was used to 
associate the IDH1 status and different study 
variables. Statistical significance was achieved when 
the p-value was less than or equal to 0.05. 
Statistic analysis were performed using 
computer program Microsoft Excel Window 7 
(Microsoft Corporation, NY, USA) and SPSS statistic 
program (SPSS Inc, Chicago, IL, USA). 
 
 
Results 
 
Clinical findings 
In a period of 5 years, 109 cases of 
intracranial gliomas were collected. The patients' age 
range from 1.5 to 73 years with a mean age of 31.19 ± 
15.36 years and a median of 32 years, most of the 
patients were in the third and fourth decades. There 
were 31 (28.44%) pediatric patients and 77 (71.55%) 
adults. Fifty eight (53.21%) were males and 51 
(46.78%) were females and the male to female ratio 
was 1.13:1 (Figure 1).  
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Figure 1: Age and sex distribution of the intracranial gliomas. 
 
Histopathological  findings 
Astrocytic tumors were the predominant types 
of glioma and those were 34 (31.19%) primary 
glioblastomas, 9 (8.25%) secondary glioblastoma, 19 
(17.43%) anaplastic astrocytomas, 16 (14.67%) low-
grade diffused fibrillary and gemistocytic 
astrocytomas,  7 (6.42%) pilocytic astrocytomas and 1 
(0.91%) subependymal giant cell astrocytoma, 
Whereas only  6 (5.50%) cases were oligodendro-
gliomas/oligoastrocytomas. Twelve (11.0%) were 
conventional ependymomas, 3 (2.75%) were 
anaplastic ependymomas. There was 1 (0.91%) 
desmoplastic infantile ganglioglioma, and 1 (0.91%) 
ganglioglioma.  
 
Grading System 
Tumors were graded according to the criteria 
established by WHO 2007 [1]. There were 10 (9.17%) 
cases grade I, 33 (30.27%) cases grade II, 23 (21.1%) 
cases grade III and the predominant grade was grade 
IV which was present in 43 (39.44%) cases as primary 
and secondary glioblastomas (Table 1). 
Table 1: The Grades and Types of Gliomas. 
Grade of 
Gliomas  
No of 
cases 
Type of Gliomas  
Total 
No % 
Grade-I 
7 Pilocytic astrocytoma  
 
10        
(9.17%) 
1 Subependymal giant cell astrocytoma 
1 Desmoplastic infantile ganglioglioma 
1 Ganglioglioma 
Grade-II 
16 Low-grade diffuse astrocytoma   
33      
(30.27%) 
5 Oligodendroglioma/oligoastrocytoma 
12 Ependymoma 
Grade-III 
19 Anaplastic astrocytoma   
23        
(21.1%) 
1 Anaplastic oligodendroglioma  
3 Anaplastic ependymoma 
Grade-IV 
34 Primary glioblastoma  43      
(39.44%) 9 Secondary glioblastoma  
Total 109  
109    
(100.0%) 
 
Gliomas were predominantly supratentorial in 
80 (73.39%) cases, mainly on the right hemisphere 
especially in temproparietal lobe and commonly in 
adult patients. In contrary 29 (26.60%) gliomas were 
infratentorial commonly in the 4
th
 ventricle, majority 
were ependymomas and pilocytic astrocytomas, and 
seen mostly in children.   
 
IDH1 and gliomas 
The 10% cells positivity were the cornerstone 
point of IDH1 mutation [2, 13].  Positive IDH1 staining 
was observed in 38 (34.86%) cases of glioma. The 
secondary glioblastoma and the low-grade diffuse 
astrocytoma represent the largest groups of IDH1 
positivity, followed by oligoastrocytoma/oligo-
dendroglioma in 50.0% of cases, and anaplastic 
astrocytoma in 47.36%. However, the p-value 
between the frequency of different types of gliomas ad 
the IDH1 positivity failed to reach a statistical 
significance value (p-value = 0.056) (Table 2). IDH1 
was evenly expressed in both sexes,  
Table 2: IDH1 Status and the Types of Gliomas. 
Types of Glioma 
Total 
No 
IDH1 positivity 
No (%) 
IDH1 Negativity 
No (%) 
P-value 
Diffuse astrocytoma 16 10 (62.5%) 6 (37.5%) 
0.056* 
Anaplastic astrocytoma 19 9 (47.36%) 10 (52.63%) 
G
li
o
b
la
s
to
m
a
 Primary glioblastoma 34 6 (17.64%) 28 (82.35%) 
Secondary glioblastoma 9 8 (88.88%) 1 (11.11%) 
Oligodendroglioma/oligoastrocytoma 6 3 (50.0%) 3 (50.0%) 
Pilocytic astrocytoma 7 1 (14.28%) 6 (85.71%) 
Ependymoma 15 1 (6.66%) 14 (93.33%) 
Subependymal giant cell astrocytoma 1 0 (0.0%) 1 (100.0%) 
Desmoplastic infantile ganglioglioma 1 0 (0.00%) 1 (100.0%) 
Ganglioglioma 1 0 (0.00%) 1 (100.0%) 
Total 109 38 (34.86%) 71 (65.13%)  
* Chi squared was used. 
 
Concerning the grades of gliomas, no 
significant relationship was identified between the 
IDH1 positivity and the different grades of the tumors 
(Table 3). 
Table 3: Correlation of IDH1 Positivity and the Grades of 
Gliomas. 
 
Grade of 
Gliomas  
Total No case 
with IDH1 
Positivity 
No of cases 
with IDH1 
Positivity 
 
Type of Gliomas  
Grade-I 1 1 Pilocytic astrocytoma 
Grade-II 12 10 Low-grade diffuse astrocytoma 
2 Oligodendroglioma/Oligoastrocytoma 
Grade-III 11 9 Anaplastic astrocytoma  
1 Anaplastic oligodendroglioma  
1 Anaplastic ependymoma 
Grade-IV 14 6 Primary glioblastoma  
8 Secondary glioblastoma 
Total 38 38  
 
Regarding the variants of glioblastoma, 4 
were giant cell type, 1 of which was IDH1 positive 
positivity for IDH1. Two were gliosarcomas, both were 
positive; also the 2 glioblastomas with primitive 
neuroectodermal tumor (PNET) components were 
positive for IDH1 with granular rather than diffuse 
cytoplasmic staining. Lastly 1 out of 2 glioblastomas 
with oligodendroglioma component showed IDH1 
cytoplasmic positivity. 
In regarding pediatric gliomas, apart from a 
single recurrent pilocytic astrocytoma and a primary 
glioblastoma which were IDH1 positive, all others 
were IDH1 negative. No oligodendrogliomas/oligo-
astrocytomas or gangliogliomas were encountered 
below 15 years of age. Difference in age distribution 
of IDH1 positivity between adult and pediatric gliomas 
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is statistically highly significant (p<0.001) (Table 4).   
Table 4: Distribution of IDH1 Reactivity and the Age-related 
Gliomas.  
Age-related Gliomas 
Total IDH1    Positivity IDH1   Negativity  
P-value* No No.            % No.          % 
Adult-related 78 36           (46.15%) 42          (53.84%)  
Pediatric-related 31 2             (6.45) 29            (93.54) <0.001 
Total 109 38           (34.86) 67          (61.46)  
*Chi squared was used. 
 
Discussion 
IDH1 mutation has became as a main 
diagnostic and prognostic biomarker for gliomas [13, 
17]. IDH1 mutations occurs in a vast majority of 
diffuse astrocytomas, oligodendrogliomas, and mixed 
oligoastrocytomas of WHO grades II and III and an 
earlier important findings in a fraction of secondary 
and primary glioblastomas [13,14,17,18]. 
 
A  B  
C  D  
E  F  
G  H  
  
Figure 2: A- Low-grade diffuse astrocytoma (IDH1 x100). B- Anaplastic astrocytoma (IDH1 x400). C- Glioblastoma (IDH1 x100). D- 
Gliosarcoma (IDH1 x400). E- Glioblastoma with PNET-like component (IDH1 x400). F- Glioblastoma with Oligodendroglioma component 
(IDH1 x400). G- Oligodendroglioma (IDH1 x100). H- Pilocytic astrocytoma (IDH1 x100). 
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The present work was the first study in Iraq to 
assess the immunohistochemical status of IDH1 
mutant in various types and grades of gliomas. In line 
with many previous studies [3-5,12,15,19-22], that 
reported a higher frequency of IDH1 mutations in 
grade II gliomas compared with grades  III and 
primary glioblastoma, the current showed highest 
IDH1 mutations among low-grade diffused 
astrocytomas (62.5%), and in secondary glioblastoma 
(88.88%), between other grades and types of gliomas. 
However, in contrast to majority of the previous 
studies [2, 3, 5,18, 19, 23-27], the present study 
clarified a relatively higher degree of expression of the 
IDH1 in primary glioblastoma (17.64%). This may be 
due to vague presentation, delay diagnosis and 
treatment of some of low grade gliomas that 
presented initially as primary glioblastomas. 
Nobusawa proposed that these primary glioblastomas 
with IDH1 mutation actually represent secondary 
glioblastomas with an unusually short clinical 
presentation [15], (Table 5). 
Table 5: The positivity of IDH1 in primary glioblastomas in 
different studies. 
IDH1 positivity No. of cases Year Region Study 
17.64% 109 2014 Iraq Current study 
39.3% 70 2013 Austria  Leibetseder [23] 
7.3% 164 2012 Japan Takano et al [19] 
16.3% 106 2011 USA Pollack et al [24] 
8.0% 131 2011 Germany Toedt et al [25] 
4.4% 100 2011 India Jha et al [26] 
6.0% 1392 2010 France Labussiere et al [27] 
4.0% 345 2009 Germany Capper et al [5] 
4.87% 445 2009 U.K Yan et al [18] 
3.0% 305 2009 Sweden Ichimura et al [3] 
7.0% 685 2008 Germany Balss et al [2] 
 
The presence of IDH1 mutation in the majority 
of low grade astrocytomas confirms the neoplastic 
nature of the lesion and helps to differentiate the 
lesser cellular infiltrative tumor and /or tumor margin 
from gliosis particularly in a stereotactic biopsy [10, 
14, 28, 29].  In the current study IDH1 positivity was 
helpful in confirming the clinical diagnosis of the 
neoplastic nature of the lesion. 
Concerning the 2 glioblastomas variant with 
PNET component, both were IDH1 positive, which 
suggest the possibility of secondary glioblastoma 
originated from this tumor or the different histogeneic 
origin of this tumor from the primary Glioblastoma. In 
contrast other similar study showed reactivity of IDH1 
in a minority of glioblastoma with PNET component 
and argue against the sole of secondary glioblastoma 
[30]. Therefore, large-scale studies are necessary to 
conclude the facts.    
In contrary to adult gliomas, pediatric low and 
high-grade gliomas did not express IDHI. There was 
only one pediatric primary glioblastoma and a 
recurrent case of pilocytic astrocytoma which 
expressed the IDH1 mutation. This is in agreement 
with other related studies [2, 4, 14, 24, 31-33], which 
concluded no role of IDH1mutation in pediatric 
gliomas. This can be explained by the frequency, 
pathological spectrum and the anatomical location of 
gliomas in this age group. So this may highlight the 
differences in the pathogenesis between pediatrics 
and adult gliomas.  
The prognostic role of IDH1 in gliomas: IDH1 
mutation demonstrated by many studies as 
associated with prolonged survival. Furthermore, 
patients with IDH mutant glioblastomas showed longer 
survival than patients with glioblastomas, or even 
anaplastic astrocytomas, without IDH mutations [18, 
21, 22, 34, 35] 
In conclusion, IDH1 mutation is commonly 
present in adult gliomas particularly low-grade 
gliomas, and secondary glioblastoma, with no sex 
predilection, but it has no role in pediatric gliomas.  
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